President Donald Trump has issued an executive order to remove restrictions on psychedelic drugs such as ibogaine, expediting their review by the U.S. Food and Drug Administration. These substances have been designated as "breakthrough therapy" drugs.
During a press briefing at the White House, Trump emphasized the importance of advancing clinical trials for these treatments to ensure their safety and efficacy for American patients. He highlighted the potential benefits of psychedelic drugs like ibogaine in addressing severe mental health conditions, particularly among military veterans at risk of suicide.
Trump's executive order aims to eliminate unnecessary regulatory barriers hindering the development of these innovative therapies. He emphasized the need to streamline processes, enhance data sharing between the FDA and the Department of Veterans Affairs, and expedite the rescheduling of psychedelic drugs approved by the FDA.
Specifically, Trump highlighted ibogaine, a plant-based psychoactive compound, citing a study from Stanford University that demonstrated significant reductions in depression and anxiety symptoms among special operation veterans with traumatic brain injuries who underwent ibogaine treatment.
The president announced a federal investment of $50 million for ibogaine research, in addition to existing commitments from Republican leaders in Texas. He also mentioned the creation of a pathway for ibogaine to be administered to critically ill patients under the right to try law.
Trump's executive order is intended to provide hope for individuals suffering from debilitating symptoms, offering them the opportunity to improve their quality of life. This move reflects the administration's growing interest in exploring alternative treatments for mental illness.
